Followers | 1076 |
Posts | 80418 |
Boards Moderated | 5 |
Alias Born | 03/10/2009 |
Wednesday, November 13, 2019 7:34:48 AM
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Verastem, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
92337C104
(CUSIP Number)
October 24, 2019
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
¨
Rule 13d-1(b)
x
Rule 13d-1(c)
¨
Rule 13d-1(d)
(Page 1 of 8 Pages)
______________________________
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 92337C104
13G
Page 2 of 8 Pages
1
NAMES OF REPORTING PERSONS
Highbridge Capital Management, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
0
6
SHARED VOTING POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
7
SOLE DISPOSITIVE POWER
0
8
SHARED DISPOSITIVE POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
IA, OO
CUSIP No. 92337C104
13G
Page 3 of 8 Pages
1
NAMES OF REPORTING PERSONS
1992 Tactical Credit Master Fund, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
0
6
SHARED VOTING POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
7
SOLE DISPOSITIVE POWER
0
8
SHARED DISPOSITIVE POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
PN
CUSIP No. 92337C104
13G
Page 4 of 8 Pages
Item 1(a).
NAME OF ISSUER:
The name of the issuer is Verastem, Inc. (the "Company").
Item 1(b).
ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
The Company's principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
Item 2(a).
NAME OF PERSON FILING:
Item 2(b).
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c).
CITIZENSHIP:
This statement is filed by:
(i)
Highbridge Capital Management, LLC
277 Park Avenue, 23rd Floor
New York, New York 10172
Citizenship: State of Delaware
(ii)
1992 Tactical Credit Master Fund, L.P.
277 Park Avenue, 23rd Floor
New York, New York 10172
Citizenship: State of Delaware
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
Item 2(d).
TITLE OF CLASS OF SECURITIES:
Common Stock, par value $0.0001 per share (the "Common Stock").
Item 2(e).
CUSIP NUMBER:
92337C104
Item 3.
IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a)
¨
Broker or dealer registered under Section 15 of the Act,
(b)
¨
Bank as defined in Section 3(a)(6) of the Act,
(c)
¨
Insurance Company as defined in Section 3(a)(19) of the Act,
(d)
¨
Investment Company registered under Section 8 of the Investment Company Act of 1940,
(e)
¨
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
CUSIP No. 92337C104
13G
Page 5 of 8 Pages
(f)
¨
Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
(g)
¨
Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
(h)
¨
Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
(i)
¨
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
¨
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k)
¨
Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
specify the type of institution:____________________________________
Item 4.
OWNERSHIP.
(a) Amount beneficially owned:
As of the date hereof, (i) Highbridge Capital Management, LLC, as the trading manager of 1992 Tactical Credit Master Fund, L.P., may be deemed to be the beneficial owner of the 4,065,183 shares of Common Stock issuable upon conversion of convertible notes held by 1992 Tactical Credit Master Fund, L.P. and (ii) 1992 Tactical Credit Master Fund, L.P. may be deemed to be the beneficial owner of the 4,065,183 shares of Common Stock issuable upon conversion of convertible notes held by it.
(b) Percent of class:
The percentages used herein and in the rest of this Schedule 13G are calculated based upon 74,349,659 shares of Common Stock reported to be outstanding, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission on October 30, 2019, and assumes the conversion of the convertible notes reported herein. Therefore, as of the date hereof, (i) Highbridge Capital Management, LLC may be deemed to beneficially own approximately 5.18% of the outstanding shares of Common Stock and (ii) 1992 Tactical Credit Master Fund, L.P. may be deemed to beneficially own approximately 5.18% of the outstanding shares of Common Stock.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock issuable upon conversion of the convertible notes held by 1992 Tactical Credit Master Fund, L.P.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote
0
CUSIP No. 92337C104
13G
Page 6 of 8 Pages
(ii) Shared power to vote or to direct the vote
See Item 4(a)
(iii) Sole power to dispose or to direct the disposition of
0
(iv) Shared power to dispose or to direct
the disposition of
See Item 4(a)
Item 5.
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
Item 6.
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
Item 7.
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
Item 8.
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
Item 9.
NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
Item 10.
CERTIFICATION.
Each Reporting Person hereby makes the following certification:
By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. 92337C104
13G
Page 7 of 8 Pages
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
DATED: November 4, 2019
HIGHBRIDGE CAPITAL MANAGEMENT, LLC
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
1992 TACTICAL CREDIT MASTER FUND, L.P.
By:
Highbridge Capital Management, LLC
its Trading Manager
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
CUSIP No. 92337C104
13G
Page 8 of 8 Pages
EXHIBIT 1
JOINT FILING AGREEMENT
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
DATED: November 4, 2019
HIGHBRIDGE CAPITAL MANAGEMENT, LLC
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
1992 TACTICAL CREDIT MASTER FUND, L.P.
By:
Highbridge Capital Management, LLC
its Trading Manager
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent VSTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:17 PM
- Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 08:05:00 PM
- Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting • Business Wire • 09/10/2024 11:30:00 AM
- Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 • Business Wire • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:42 PM
- Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 08/08/2024 08:05:00 PM
- Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer • Business Wire • 07/29/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 09:06:01 PM
- Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/24/2024 03:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/23/2024 08:33:23 PM
- Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:17 PM
- Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics • Business Wire • 07/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 11:00:18 AM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/08/2024 11:30:00 AM
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:56 PM
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 05/09/2024 08:02:00 PM
- Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM